Sugi Predict

Sugi Predict / Targets / PLA2G4B

PLA2G4B

Cytosolic phospholipase A2 beta · P0C869 · PLA2G4B on Sugi Atlas →

47,611 patent compounds predicted against PLA2G4B, 32,612 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL371494 SCHEMBL371494 0.97 8/20
SCHEMBL503352 SCHEMBL503352 0.97 8/20
SCHEMBL503367 SCHEMBL503367 0.97 8/20
SCHEMBL503567 SCHEMBL503567 0.97 8/20
SCHEMBL503568 SCHEMBL503568 0.97 8/20
SCHEMBL503946 SCHEMBL503946 0.97 8/20
SCHEMBL503960 SCHEMBL503960 0.97 8/20
SCHEMBL503727 SCHEMBL503727 0.93 8/20
SCHEMBL123687 SCHEMBL123687 0.74 8/20
SCHEMBL509130 SCHEMBL509130 0.70 8/20
SCHEMBL123688 SCHEMBL123688 0.65 8/20
SCHEMBL249863 SCHEMBL249863 0.52 8/20
SCHEMBL302564 SCHEMBL302564 0.80 7/20
SCHEMBL304398 SCHEMBL304398 0.80 7/20
SCHEMBL209561 SCHEMBL209561 0.79 7/20
SCHEMBL175191 SCHEMBL175191 0.74 7/20
SCHEMBL223467 SCHEMBL223467 0.70 7/20
SCHEMBL303109 SCHEMBL303109 0.70 7/20
SCHEMBL303140 SCHEMBL303140 0.70 7/20
SCHEMBL430092 SCHEMBL430092 0.70 7/20

Clinical trials — most relevant to PLA2G4B by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Comparison of Simvastatin Versus Simvastatin/Ezetimibe on Small Dense Low -Density Lipoprotein (LDL) PHASE4COMPLETED
A Randomized Controlled Pilot Trial of Indomethacin in Acute Pancreatitis PHASE3COMPLETED
European Celecoxib Trial in Primary Breast Cancer PHASE3COMPLETED
Aspirin and Renal Disease Progression in Patients With Type 2 Diabetes PHASE3UNKNOWN
Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With PM and DM PHASE3COMPLETED
Montelukast in Parkinson Disease PHASE2/PHASE3RECRUITING
Montelukast for Early Life Wheezing PHASE2/PHASE3COMPLETED
Lovaza's Effect on the Activation of Platelets PHASE2COMPLETED
Ibuprofen Versus Acetaminophen for Treatment of Mild Traumatic Brain Injury PHASE2WITHDRAWN
Effect of Gemfibrozil on Serum Glycosylphosphatidylinositol (GPI) Phospholipase D and Triglycerides PHASE1COMPLETED
Role of PLA2G1B During HIV Infection nanUNKNOWN
Plasma Free Fatty Acids Profile As A Diagnostic Tool For Acute Ischemic Stroke nanCOMPLETED
EPICO: (Study for the Pro-resolution of Chronic Inflammation in Obesity. Original Acronym From Spanish) nanUNKNOWN
Investigation of Lipoxin A4, Annexin A1 and Interleukin-1 Beta Levels in Individuals With Periodontitis. nanCOMPLETED
Mucomyst for Hepatitis C nanSUSPENDED
Lipoprotein-associated Phospholipase A2 in Patients With Type 2 Diabetes nanCOMPLETED
Positron Emission Tomography (PET) to Study Brain Signaling nanCOMPLETED
Molecular Markers of Human Sperm Function nanWITHDRAWN
PET Imaging of DHA Metabolism nanCOMPLETED
LDL-Apheresis for FSGS CardioRenal Outcomes nanCOMPLETED
The Association Between Post-ERCP Acute Pancreatitis and Various Genetic Mutations nanCOMPLETED
In-vivo Thrombus Imaging With 18F-GP1, a Novel Platelet PET Radiotracer nanCOMPLETED
Autotaxin (ATX) as a Marker for Breast Cancer nanUNKNOWN
High Dose Omega-3 Fatty Acids in the Treatment of Sport Related Concussions nanCOMPLETED
Validation of an Assay to Measure Cyclooxygenase-1 Activity nanCOMPLETED
Lp-PLA2 and Coronary Atherosclerosis in Humans nanCOMPLETED
Eicosanoid Lipids by Airway Cells During Infection With Human Rhinoviruses nanCOMPLETED
Computed Tomography and Biomarker Analysis in Diagnosing Coronary Artery Disease in Asymptomatic Patients Who Have Undergone Stem Cell Transplant nanCOMPLETED
Genetic Markers of CHD Risk in Men and Women nanCOMPLETED
Evaluation of Plasma Sphingosine-1-Phosphate as A Diagnostic and Prognostic Biomarkers of Community-Acquired Pneumonia nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a PLA2G4B binder may also engage these)

ProteinNameSimilarity
Q68DD2 — 1.000 Q68DD2 →
P0C871 — 0.998 P0C871 →
Q86XP0 — 0.997 Q86XP0 →
Q50L41 — 0.993 Q50L41 →
Q50L43 — 0.989 Q50L43 →
Q3MJ16 — 0.986 Q3MJ16 →
Q9ESK3 — 0.981 Q9ESK3 →
Q8VDP3 — 0.978 Q8VDP3 →
Q9HC96 — 0.978 Q9HC96 →
E9QAM5 — 0.977 E9QAM5 →
Q50L42 — 0.977 Q50L42 →
Q91ZJ0 — 0.976 Q91ZJ0 →
Q865R1 — 0.976 Q865R1 →
Q643R3 — 0.976 Q643R3 →
ENGASE Cytosolic endo-beta-N-acetylglucosaminidase 0.976 landscape →
D3ZBP4 — 0.976 D3ZBP4 →
Q91W34 — 0.976 Q91W34 →
Q9ES66 — 0.976 Q9ES66 →
A6H751 — 0.976 A6H751 →
FLAD1 FAD synthase 0.976 landscape →
Q8TDZ2 — 0.975 Q8TDZ2 →
Q95LP4 — 0.975 Q95LP4 →
P49222 — 0.975 P49222 →
PLA2G4C Cytosolic phospholipase A2 gamma 0.975 landscape →
Q6MG21 — 0.975 Q6MG21 →
Q767M3 — 0.974 Q767M3 →
P54777 — 0.974 P54777 →
A7E3S5 — 0.974 A7E3S5 →
P10937 — 0.974 P10937 →
Q149M9 — 0.974 Q149M9 →